(KLA dri been)


Use: Labeled Indications

Treatment of active hairy cell leukemia


Hypersensitivity to cladribine or any component of the formulation

ALERT: U.S. Boxed Warning

Experienced physician:

Cladribine should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.

Bone marrow suppression:

Anticipate suppression of bone marrow function. This is usually reversible and appears to be dose dependent.


Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Renal toxicity:

Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for hairy cell leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.